American Diabetes Association 75th Scientific Sessions

June 5-9, 2015; Boston, MA; Category Document

ADA 2015 Category Document: Notable Posters

This category document features our top picks for some of the conference’s thousands of posters. Assembling the list was a tough task given that there are over 2,200 general and late-breaking posters expected at this year’s poster hall. We would like to note that there are many posters of high importance not included on this list. We’re interested in your opinion on what we missed – and we emphasize that there were far too many to include. Please write us with your opinions on our choices if you find any variance.

Table of Abstract Titles

Abstract ID

Title

Authors

Room

Date

Time

2-LB

Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of BIOD-961 Compared with Marketed Glucagons

LILIANA URIBE-BRUCE, LINDA MORROW, LORI CANNEY, PHILIP PICHOTTA, MARCUS HOMPESCH, ALAN KRASNER, ERROL DE SOUZA, Chula Vista, CA, Danbury, CT

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

5-LB

Incidence of Hypoglycemia Overtreatment in the SHARE Real Life Use Population

KATHERINE NAKAMURA, TOMAS WALKER, JAKE LEACH, LUCAS BOHNETT, JORGE VALDES, ANDREW BALO, San Diego, CA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

15-LB

Cardiovascular Outcomes of Saxagliptin Treatment in African Americans with Type 2 Diabetes: Results from the SAVOR-TIMI 53 Trial

SAMUEL DAGOGO-JACK, KWAME OSEI, BENJAMIN M. SCIRICA, LAWRENCE A. LEITER, KYUNGAH IM, BOAZ HIRSHBERG, ITAMAR RAZ, DEEPAK L. BHATT, SAVOR-TIMI 53 STEERING COMMITTEE AND INVESTIGATORS, Memphis, TN, Columbus, OH, Boston, MA, Toronto, ON, Canada, Wilmington, DE, Jerusalem, Israel

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

49-LB

The Relationship between Online Activity & Biometric Tracking and Medication Adherence among Members with Diabetes

MICHAEL TAITEL, JENNY JIANG, OSAYI AKINBOSOYE, GREGORY ORR, Deerfield, IL

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

66-LB

“It Is Definitely a Game Changer”: Closed Loop Technology in the Home Experienced by Adults with Type 1 Diabetes

CHRISTEL HENDRIECKX, JANE SPEIGHT, LUCINDA A. POOLE, AMIN SHARIFI, MARGARET LOH, JODIE C. HORSBURGH, STEVE TRAWLEY, ALICIA J. JENKINS, KAVITA KUMARESWARAN, RICHARD J. MACISAAC, GLENN M. WARD, PETER COLMAN, LEON A. BACH, ANDREW KYOONG, NATALIE KURTZ, BENYAMIN GROSMAN, ANIRBAN ROY, DAVID O'NEAL, Melbourne, Australia, Fitzroy, Australia, Northridge, CA

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

71-LB

 

 

Imprecision of SMBG Values Used for CGM Calibration during Optimal Conditions or Home Use

ARTURO GARCIA, TOMAS WALKER, DAVID A. PRICE, San Diego, CA

 Hall B - Poster Hall

7 -Jun

12:00 PM - 2:00 PM

72-LB

Comparative Accuracy of 17 Glucometers

LAYA EKHLASPOUR, MANASI SINHA, DEBBIE MONDESIR, NORMAN LAUTSCH, COURTNEY BALLIRO, MALLORY HILLARD, KENDRA MAGYAR, STEVEN J. RUSSELL, Boston, MA, Cambridge, MA

 Hall B - Poster Hall

7 -Jun

12:00 PM - 2:00 PM

84-LB

 A New Ultra-Long-Acting Glargine Analog with Improved Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles Compared with Lantus®

YOU-PING CHAN, GUILLAUME NOEL, Oullins, France, Marcy l'Etoile, France

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

91-LB

Improved Glycemic Control with Lesser Daily Dose with insulin Glargine on Retransition from Insulin Detemir

UDAYA M. KABADI, Iowa City, IA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

92-LB

Ultra-Rapid-Acting/Basal Concentrated Insulin BIOD-531 Demonstrates Superior Postprandial Glucose Control and Potential for Flexible Post-meal Dosing Compared with Marketed Prandial/Basal Insulins in Insulin-Resistant Patients with Type 2 Diabetes

LINDA MORROW, LORI CANNEY, PHILIP PICHOTTA, MARCUS HOMPESCH, ALAN KRASNER, ERROL DE SOUZA, Chula Vista, CA, Danbury, CT

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

95-LB

New Insulin Glargine 300 U/mL (Gla-300) in Combination with Dipeptidyl Peptidase IV Inhibitors in T2DM (EDITION 2 and 3): Glycemic Control and Hypoglycemia

RAFFAELLA BUZZETTI, JEREMY H. PETTUS, MIGUEL BRITO-SANFIEL, FERNANDO J. LAVALLE-GONZÁLEZ, ANA MERINO-TRIGO, PETER STELLA, SOAZIG CHEVALIER, JEAN-FRANÇOIS YALE, Rome, Italy, San Diego, CA, Majadahonda, Spain, Monterrey, Mexico, Paris, France, Chilly-Mazarin, France, Montreal, QC, Canada

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

96-LB

Efficacy and Safety of Technosphere Inhaled Insulin: Systematic Review and Meta-analysis

GREGORY P. WESTCOTT, ETHAN M. BALK, ANASTASSIOS G. PITTAS, Boston, MA, Providence, RI

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

98-LB

Bi-hormonal Closed-Loop Treatment of Type 1 Diabetes with Exercise Announcement to Prevent Hypoglycemia

PETER G. JACOBS, JOSEPH EL YOUSSEF, NAVID RESALAT, RAVI REDDY, DEBORAH BRANIGAN, NICHOLAS PREISER, JOHN CONDON, JESSICA R. CASTLE, Portland, OR

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

99-LB

Closed-Loop Control with DiAs vs. Sensor-Augmented Pump Therapy in Adolescents and Young Adults with Type 1 Diabetes at Camp

TRANG T. LY, DANIEL CHERÑAVVSKY, MARTA SATIN-SMITH, DANIEL J. DESALVO, SATYA SHANMUGHAM, PATRICK KEITH-HYNES, MARC D. BRETON, BRUCE A. BUCKINGHAM, Stanford, CA, Charlottesville, VA, Norfolk, VA

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

100-LB

Medtronic’s Hybrid Closed-Loop System – An Evaluation of Meal Dosing

BENYAMIN GROSMAN, ANIRBAN ROY, GAYANE VOSKANYAN, NATALIE KURTZ, DI WU, NEHA PARIKH, REBECCA GOTTLIEB, KRISTEN HUGHES, SARAH MCKENNEY, RONALD BRAZG, FRANCINE KAUFMAN, Northridge, CA, Renton, WA

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

101-LB

Dose Safety Artificial Pancreas Controller Use in Ad Lib Living Studies

RICHARD MAUSETH, DON MATHESON, ROBERT KIRCHER, Redmond, WA

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

105-LB

Once-a-Month Treatment with HM11260C Improves Glycemic Control in Type 2 Diabetes (T2DM)—Interim Data from a 16-Week Study

STEFANO DEL PRATO, JAHOON KANG, SOOMIN CHOI, WOOHYUNG LEE, OAKPIL HAN, SIYOEN KIL, KYUHOON GEE, IN YOUNG CHOI, SE CHANG KWON, MICHAEL TRAUTMANN, MARCUS HOMPESCH, Pisa, Italy, Seoul, Korea, Republic of, Hwaseong, Korea, Republic of, Hamburg, Germany, Chula Vista, CA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

107-LB

Advancing Basal Insulin Glargine with Prandial Lixisenatide QD vs. Insulin Glulisine QD or TID in T2DM: The GetGoal-Duo2 Evidence-Based Trial (NCT01768559)

JULIO ROSENSTOCK, MARKOLF HANEFELD, SANDRO GENTILE, RONNIE ARONSON, FRANCISCO J. TINAHONES, BRUNO GUERCI, CHRISTINE ROY-DUVAL, ELISABETH SOUHAMI, MAREK WARDECKI, JENNY YE, SIMON HELLER, ON BEHALF OF THE GETGOAL-DUO2 STUDY INVESTIGATORS, Dallas, TX, Dresden, Germany, Naples, Italy, Toronto, ON, Canada, Málaga, Spain, Vandœuvre-lès-Nancy, France, Paris, France, Warsaw, Poland, Bridgewater, NJ, Sheffield, United Kingdom

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

111-LB

Cardiovascular Outcome Trial with Fasiglifam, a Novel Selective GPR 40 Agonist

VENU MENON, A. MICHAEL LINCOFF, STEPHEN NICHOLLS, PRABHAKAR VISWANATHAN, DARREN K. MCGUIRE, THEODORE MAZZONE, BERNARD ZINMAN, ANTONIO CHACRA, JOHN BETTERIDGE, JULIO ROSENSTOCK, CYRUS MEHTA, SUSAN JASPER, JOHN MARCINAK, CLAUDIA LOPEZ, STEVEN E. NISSEN, Cleveland, OH, Adelaide, Australia, Deerfield, IL, Dallas, TX, Chicago, IL, Toronto, ON, Canada, São Paulo, Brazil, London, United Kingdom, Cambridge, MA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

114-LB

Baricitinib in Diabetic Kidney Disease: Results from a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

KATHERINE R. TUTTLE, FRANK C. BROSIUS III, SHARON G. ADLER, MATTHIAS KRETZLER, RAVINDRA L. MEHTA, JAMES A. TUMLIN, JIAJUN LIU, MARIA E. SILK, TRACY E. CARDILLO, KEVIN L. DUFFIN, JOSEPH V. HAAS, WILLIAM L. MACIAS, JONATHAN M. JANES, Spokane, WA, Ann Arbor, MI, Torrance, CA, San Diego, CA, Chattanooga, TN, Indianapolis, IN

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

130-LB

The Combination of Insulin, Liraglutide, and Dapagliflozin as Triple Therapy for Type 1 Diabetes

NITESH D. KUHADIYA, ADITYA MEHTA, HUSAM GHANIM, JEANNE HEJNA, ANTOINE MAKDISSI, AJAY CHAUDHURI, MANAV BATRA, PARESH DANDONA, Buffalo, NY

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

133-LB

Triple Therapy with Dapagliflozin (DAPA) Add-on to Saxagliptin (SAXA) plus Metformin (MET): Characterization of the Open-Label SAXA+MET Lead-in Period of a Phase 3 Trial

CHANTAL MATHIEU, AURELIAN EMIL RANETTI, LARS HANSEN, HUNTGA CHEN, RICARDO GARCIA-SANCHEZ, ALEX J. CHIN, NAYYAR IQBAL, Leuven, Belgium, Bucharest, Romania, Princeton, NJ, Gaithersburg, MD

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

139-LB

CMS Competitive Bidding Program Disrupted Access to Diabetes Supplies with Resultant Increased Mortality

GARY A. PUCKREIN, FARHAD ZANGENEH, GAIL NUNLEE-BLAND, LIOU XU, CHRISTOPHER G. PARKIN, JAIME A. DAVIDSON, Washington, DC, Boulder City, NV, Dallas, TX

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

145-LB

HOMA2ß Is Predictive of the Development of Type 1 Diabetes in TrialNet Pathway to Prevention Participants

FARAH MEAH, PING XU, LINDA A. DIMEGLIO, JAY M. SOSENKO, SUSAN GEYER, CARMELLA EVANS-MOLINA, TYPE I DIABETES TRIALNET GROUP, Indianapolis, IN, Tampa, FL, Miami, FL

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

149-LB

Antibiotic Use in Early Childhood and the Development of Type 1 Diabetes Autoimmunity: The TEDDY Study

KAISA M. KEMPPAINEN, KENDRA VEHIK, RONALD J. CANEPA, ALEXANDRIA N. ARDISSONE, AUSTIN G. DAVIS-RICHARDSON, OLLI G. SIMELL, JORMA TOPPARI, ANETTE G. ZIEGLER, MARIAN REWERS, ÅKE LERNMARK, WILLIAM A. HAGOPIAN, JIN-XIONG SHE, BEENA AKOLKAR, DESMOND SCHATZ, MARK A. ATKINSON, MARTIN J. BLASER, JEFFREY P. KRISCHER, ERIC W. TRIPLETT, TEDDY STUDY GROUP, Gainesville, FL, Tampa, FL, Turku, Finland, Munich, Germany, Aurora, CO, Malmö, Sweden, Seattle, WA, Augusta, GA, Bethesda, MD, New York, NY

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

164-LB

Risk of Hospitalization for Heart Failure with Dipeptidyl Peptidase-4 Inhibitors vs. Sulfonylureas and with Saxagliptin vs. Sitagliptin in a U.S. Claims Database

ALEX Z. FU, STEPHEN JOHNSTON, JOHN SHEEHAN, AMEEN GHANNAM, KATHERINE TSAI, KATHERINE CAPPELL, ROBERT FOWLER, IFTEKHAR KALSEKAR, Washington, DC, Bethesda, MD, Fort Washington, PA, Gaithersburg, MD

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

169-LB

Bladder Cancer Risk in Relation to Exposure to Pioglitazone among Patients with T2DM in the Pan European Multi-Database Bladder Cancer Risk Characterisation Study

PASI KORHONEN, EDITH M. HEINTJES, RACHAEL WILLIAMS, FABIAN HOTI, SOLOMON CHRISTOPHER, MAILA MAJAK, LEANNE HOUWELING, HELEN STRONGMAN, MARIE LINDER, PAUL DOLIN, SHAHRAM BAHMANYAR, Espoo, Finland, Utrecht, Netherlands, London, United Kingdom, Stockholm, Sweden

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

180-LB

Reduction in Diabetes Incidence Differs by Prediabetes Type in a Randomized Translational Trial of Prevention

MARY BETH WEBER, HARISH RANJANI, LISA R. STAIMEZ, RANJIT M. ANJANA, MOHAMMED K. ALI, K.M. VENKAT NARAYAN, VISWANATHAN MOHAN, Atlanta, GA, Chennai, India

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

221-LB

Ten-Year Outcomes after Islet Transplantation with the Edmonton Immunosuppression Protocol in Patients with Type 1 Diabetes

MARIE CHRISTINE VANTYGHEM, JULIE KERR-CONTE, FRANÇOIS PATTOU, Lille, France

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

299-LB

Impact of Sulfonylurea (SFU) Use on Weight Loss (WL) Achieved with Lorcaserin (LOR)

CAROLINE M. APOVIAN, RANDI FAIN, ALAN GLICKLICH, TONY MA, WILLIAM SHANAHAN, Boston, MA, Woodcliff Lake, NJ, San Diego, CA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

301-LB

Established BMI-associated Genetic Variants and Their Longitudinal Associations with Cardiometabolic Traits: The GLACIER Study

SHAFQAT AHMAD, ALAITZ POVEDA, DMITRY SHUNGIN, INÊS BARROSO, GÖRAN HALLMANS, FRIDA RENSTRÖM, PAUL W. FRANKS, Malmö, Sweden, Umeå, Sweden, Cambridge, United Kingdom

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

307-LB

Liraglutide 3.0 mg Efficacy and Safety by Baseline BMI in the SCALE Diabetes Trial: Post-hoc Analysis

VANITA R. ARODA, JULIO ROSENSTOCK, JOANNA UDDÉN HEMMINGSSON, MELANIE DAVIES, TRINE V. SKJØTH, BIRGITTE CLAUDIUS, HAROLD BAYS, Hyattsville, MD, Dallas, TX, Stockholm, Sweden, Leicester, United Kingdom, Søborg, Denmark, Louisville, KY

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

417-P

The Artificial Pancreas: Evaluating Risk of Hypoglycemia following Errors That Can Be Expected with Prolonged At-Home Use

 GARRY M. STEIL, MICHAEL KAVANAGH, ASTRID ATAKOV-CASTILLO, HOWARD A. WOLPERT, Boston, MA

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

419-P

Nonaqueous, Mini-dose Glucagon for Treatment of Moderate Hypoglycemia in T1D Adults: A Dose-Seeking Study

MOREY W. HAYMOND, MARIA J. REDONDO, SIRIPOOM V. MCKAY, MARTIN J. CUMMINS, BRETT J. NEWSWANGER, JOHN KINZELL, STEVEN J. PRESTRELSKI, Houston, TX, Austin, TX

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

423-P

Is Hypoglycemia a Modifiable Patient Risk in Type 2 Diabetes? A Pooled Analysis of Insulin Glargine 300U/mL (Gla-300) vs. 100U/mL (Gla-100) Trials

JULIO ROSENSTOCK, QUANWU ZHANG, CHARLES GERRITS, LAURA LIAO, PAUL CHEW, Dallas, TX, Bridgewater, NJ

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

432-P

A Diabetes Risk Score for Cardiovascular Events in Primary and Secondary Prevention—Observations from the SAVOR-TIMI 53 Study

BENJAMIN M. SCIRICA, DEEPAK L. BHATT, ITAMAR RAZ, RALPH D'AGOSTINO, JOSEPH M. MASSARO, LANYU LEI, YANG SONG, P.H. GABRIEL STEG, EUGENE BRAUNWALD, Boston, MA, Jerusalem, Israel, Paris, France

 Hall B - Poster Hall

8-Jun

12:00 PM - 2:00 PM

504-P

Risk of Cardiovascular Events with the Use of Sulfonylureas—Post Hoc Analysis from the SAVOR Trial

AVIVIT CAHN, OFRI MOSENZON, BOAZ HIRSHBERG, CHRISTINA A.M.. STAHRE, RONALD C. MA, GYORGY JERMENDY, FRANÇOIS BONNICI, KAUSIK RAY, CHERYL WEI, ITAMAR RAZ, Jerusalem, Israel, Gaithersburg, MD, Gothenburg, Sweden, Hong Kong, China, Budapest, Hungary, Cape Town, South Africa, London, United Kingdom

 Hall B - Poster Hall

8-Jun

12:00 PM - 2:00 PM

607-P

The Effect of 1-Year Sensor Augmented Insulin Pump Treatment on Albuminuria in Type 1 Diabetes: A Randomized Controlled Trial

SIGNE ROSENLUND, TINE W. HANSEN, PETER ROSSING, STEEN ANDERSEN, Gentofte, Denmark, Hillerød, Denmark

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

881-P

Frequency of Continuous Glucose Monitoring (CGM) Wear in Youth with Type 1 Diabetes (T1D): Association with Psychosocial Variables

REBECCA K. SNELGROVE, JESSICA T. MARKOWITZ, LISA VOLKENING, ANITA KAO, RYAN BUSHA, LORI M. LAFFEL, Boston, MA

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

909-P

Mobile Prescription Therapy: The Potential for Patient Engagement to Enhance Outcomes

JOSHUA L. COHEN, ANAND IYER, MALINDA PEEPLES, MANSUR E. SHOMALI, Washington, DC, Baltimore, MD

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

929-P

Patient Responses to Interim Data from Cardiovascular Outcomes Trials: Results from an Online Patient Survey

MANU V. VENKAT, RICHARD S. WOOD, ADAM S. BROWN, PHIN YOUNGE, LISA S. ROTENSTEIN, KELLY L. CLOSE, San Francisco, CA, Boston, MA

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

932-P

Glycemic Effects of SGLT2 Inhibitor Canagliflozin in Type 1 Diabetes Using Dexcom G4 Platinum CGM

NICHOLAS B. ARGENTO, KATHERINE NAKAMURA, Columbia, MD, San Diego, CA

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

934-P

Examining the Role of Continuous Glucose Monitoring (CGM) in Noninsulin Treated Type 2 Diabetes

    LAURA A. YOUNG, MICHELLE DUCLOS, ALISON MARQUIS, YANPING TENG, SONIA DAVIS, BRUCE W. BODE, JOHN B. BUSE, Chapel Hill, NC, Atlanta, GA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

935-P

The Performance of an Orthogonally Redundant Glucose Sensor Compared with a Simply Redundant Electrochemical Glucose Sensor in Adults with Type 1 Diabetes

    SYBIL A. MCAULEY, TRI T. DANG, JODIE C. HORSBURGH, ANUBHUTI BANSAL, GLENN M. WARD, ALICIA J. JENKINS, RICHARD J. MACISAAC, RAJIV V. SHAH, DAVID N. O'NEAL, Melbourne, Australia, Northridge, CA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

940-P

Reduction of Hyper- and Hypoglycemia during Two Months with a Wearable Artificial Pancreas from Dinner to Breakfast in Patients with Type 1 Diabetes

ERIC RENARD, J HANS DEVRIES, CLAUDIO COBELLI, LALO MAGNI, JEROME PLACE, JORT KROPFF, SIMONE DEL FAVERO, ROBERTO VISENTIN, MARCO MONARO, CHIARA TOFFANIN, FEDERICO DI PALMA, GIORDANO LANZOLA, MIRKO MESSORI, ANNE FARRET, FEDERICO BOSCARI, SILVIA GALASSO, DANIELA BRUTTOMESSO, ANGELO AVOGARO, AP@HOME CONSORTIUM, Montpellier, France, Amsterdam, Netherlands, Padova, Italy, Pavia, Italy

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

2656-P

Accuracy Performance of Six Self-Monitoring Blood Glucose Systems

 MAXWELL C. KUM, KALAYIL MANIAN MANESH, STEVEN CHIALIN WANG, TIMOTHY S. BAILEY, San Diego, CA, Fort Lauderdale, FL, Escondido, CA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

945-P

Mean Absolute Relative Difference (MARD) and Compliance with ISO 15197 Accuracy Limits: Which MARD Is Acceptable?

 GUIDO FRECKMANN, STEFAN PLEUS, DELIA RITTMEYER, THOMAS LEUCHT, CORNELIA HAUG, Ulm, Germany

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

947-P

Habits of Highly Successful CGM Users

 JEREMY PETTUS, ERIC EBNER, STEVEN EDELMAN, DAVID A. PRICE, La Jolla, CA, San Diego, CA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

955-P

Extended Wear of a Next Generation of CGM Sensor

 LUCAS BOHNETT, KATHERINE NAKAMURA, LAUREN JEPSON, JAKE LEACH, San Diego, CA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

956-P

Performance of Two Continuous Glucose Measurement Devices, in Closed and Open Loop System, in Pediatric Patients with Type 1 Diabetes

ULRIKE SCHIERLOH, MALGORZATA E. WILINSKA, PETRA M. BAUMANN, THOMAS AUGUSTIN, CARINE DE BEAUFORT, ROMAN HOVORKA, THOMAS R. PIEBER, SPIDIMAN STUDY GROUP, Luxembourg, Luxembourg, Cambridge, United Kingdom, Graz, Austria

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

964-P

Periodic CGM in T2DM: Exploring Benefits across Various Therapy Choices

JOTHYDEV KESAVADEV, PRADEEP BABU SADASIVAN. PILLAI, ARUN SHANKAR, GEETHU SANAL, JAYASREE LALLY, GOPIKA KRISHNAN, SUNITHA JOTHYDEV, Trivandrum, India

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

978-P

Dance-501 Inhaled Human Insulin Has a Dose-Linear Response and Similar Within-Subject Variability as Rapid-Acting Insulin Lispro

ERIC ZIJLSTRA, TIM HEISE, LESZEK NOSEK, HANS-VEIT COESTER, KATHRIN LÜCKEMEYER, LISA PORTER, SAMANTHA MILLER, ANDY VICK, JAMES B. FINK, JOHN PATTON, Neuss, Germany, Brisbane, CA, Ashland, OH

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

979-P

Ultra-Rapid BioChaperone Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)

GRIT ANDERSEN, BERTRAND ALLUIS, GRÉGORY MEIFFREN, AYMERIC RANSON, CYRIL SEROUSSI, MARTIN GAUDIER, OLIVIER SOULA, ANNELIE FISCHER, LESZEK NOSEK, TIM HEISE, Neuss, Germany, Lyon, France

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

984-P

Superior HbA1c Reduction with Basal Insulin Peglispro (BIL) vs. Insulin Glargine (GL) Alone or with Oral Antihyperglycemic Medications (OAMs) in T2D Patients (Pts) Previously Treated with Basal Insulin: IMAGINE 5

JOHN B. BUSE, HELENA W. RODBARD, CARLOS TRESCOLI SERRANO, JUNXIANG LUO, TIBOR IVÁNYI, JULIANA BUE-VALLESKEY, MARK L. HARTMAN, MICHELLE A. CAREY, ANNETTE M. CHANG, Chapel Hill, NC, Rockville, MD, Valencia, Spain, Indianapolis, IN, Budapest, Hungary, Blue Bell, PA

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

985-P

Superior HbA1c Reduction with Basal Insulin Peglispro (BIL) vs. Insulin Glargine (GL) and Preprandial Insulin Lispro in a Double-Blind Study in Patients (pts) with Type 2 Diabetes (T2D): IMAGINE 4

THOMAS BLEVINS, THOMAS R. PIEBER, GILDRED COLÓN VEGA, SHUYU ZHANG, EDWARD J. BASTYR III, ANNETTE M. CHANG, Austin, TX, Graz, Austria, San Juan, PR, Indianapolis, IN

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

986-P

Superior Reduction of HbA1c in a Double-Blind, Randomized Study of Basal Insulin Peglispro (BIL) vs. Insulin Glargine (GL) in Patients (pts) with T1D: IMAGINE 3

RICHARD M. BERGENSTAL, HELEN LUNT, EDWARD FRANEK, FLORENCE TRAVERT, JIANI MOU, MARK L. HARTMAN, MYRIAM ROSILIO, EDWARD J. BASTYR III, FOR THE IMAGINE 3 STUDY GROUP, Minneapolis, MN, Christchurch, New Zealand, Warsaw, Poland, Paris, France, Indianapolis, IN, Neuilly sur Seine, France

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

989-P

Liver Enzyme Results from 7 Basal Insulin Peglispro (BIL) Clinical Trials in T1D and T2D

MARK L. HARTMAN, SHUYU ZHANG, EDWARD J. BASTYR III, ANNETTE M. CHANG, SCOTT J. JACOBER, MELVIN J. PRINCE, Indianapolis, IN

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

990-P

Lipid Changes during 26-Wk Treatment with the Novel Basal Insulin Peglispro (BIL) vs. Insulin Glargine (GL) or Insulin NPH in 6 IMAGINE Trials

HENRY GINSBERG, BERTRAND CARIOU, TREVOR J. ORCHARD, LEI CHEN, JUNXIANG LUO, EDWARD J. BASTYR III, JULIANA BUE-VALLESKEY, ANNETTE M. CHANG, TIBOR IVÁNYI, SCOTT J. JACOBER, JENNIE G. JACOBSON, BYRON J. HOOGWERF, New York, NY, Nantes, France, Pittsburgh, PA, Indianapolis, IN, Budapest, Hungary

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

994-P

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Subjects with Type 1 Diabetes Using CSII

BRUCE BODE, LISELOTTE HYVELED, SØREN CAN TAMER, PATRIA YBANEZ, MAREK DEMISSIE, Atlanta, GA, Søborg, Denmark

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1003-P

IDegLira in Insulin-Naïve Patients with Type 2 Diabetes (T2D) Inadequately Controlled on Sulfonylureas (SU) Alone or in Combination with Metformin: The DUAL IV Study

HELENA W. RODBARD, BRUCE W. BODE, STEWART B. HARRIS, LUDGER ROSE, LUCINE LEHMANN, HENRIK JARLOV, JERRY THURMAN, Rockville, MD, Atlanta, GA, London, ON, Canada, Münster, Germany, Søborg, Denmark, Saint Charles, MO

 Hall B - Poster Hall

6-Jun

11:30 AM  - 1:30 PM

1005-P

Faster-Acting Insulin Aspart Using Continuous Subcutaneous Insulin Infusion (CSII): Earlier Onset of Exposure and Greater Early Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects than Insulin Aspart

TIM HEISE, ERIC ZIJLSTRA, TORD RIKTE, LARS THORSSON, LESZEK NOSEK, HANNE HAAHR, Neuss, Germany, Søborg, Denmark

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1016-P

Ultra-Rapid-Acting Concentrated Insulin BIOD-531 Suitability for Continuous Subcutaneous Insulin Infusion (CSII) Therapy

RODERIKE POHL, ALAN KRASNER, BRYAN R. WILSON, MING LI, MARY GUINNESS, PRAGATI RAVULA, ERROL DE SOUZA, Danbury, CT

 Hall B - Poster Hall

6-Jun

11:30 AM- 1:30 PM

1022-P

Comparative PK and PD of the Rapid-Acting Insulin Lispro Product SAR342434, and U.S.- and EU-approved Humalog® in Subjects with T1DM

IRENE NOWOTNY, CHRISTOPH KAPITZA, ANNE LEHMANN, HOOTAN KHATAMI, KARIN BERGMANN, BAERBEL ROTTHAEUSER, REINHARD BECKER, Frankfurt, Germany, Neuss, Germany, Bridgewater, NJ

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1040-P

Efficacy, Patient-Reported Outcomes (PRO), and Safety of Insulin Degludec U200 vs. Insulin Glargine in Patients with Type 2 Diabetes (T2D) Requiring High-Dose Insulin

MARK WARREN, LOUIS B. CHAYKIN, SERGE JABBOUR, MAE SHEIKH-ALI, CHARLOTTE T. HANSEN, SØREN RASMUSSEN, PAUL NORWOOD, Greenville, NC, Bradenton, FL, Philadelphia, PA, Jacksonville, FL, Søborg, Denmark, Fresno, CA

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1051-P

Efficacy of Switching from Insulin Glargine to Insulin Degludec in Patients with Type 1 Diabetes: A 52-Week Retrospective Study

JUN SUZUKI, TADASHI YAMAKAWA, JOE NAGAKURA, Yokohama, Japan

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1058-P

Preprandial Oral Insulin (ORMD-0801) Reduces Rapid-Acting Insulin Requirements and Fasting Glucose Levels in T1DM Patients

MIRIAM KIDRON, JOEL M. NEUTEL, EHUD ARBIT, Jerusalem, Israel, Tustin, CA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1060-P

Glucagon Nasal Powder: An Effective Alternative to Intramuscular Glucagon in Youth with Type 1 Diabetes

JENNIFER L. SHERR, KATRINA J. RUEDY, NICOLE C. FOSTER, CLAUDE A. PICHÉ, HÉLÈNE DULUDE, MICHAEL R. RICKELS, WILLIAM V. TAMBORLANE, KATHLEEN E. BETHIN, LINDA A. DIMEGLIO, PAUL WADWA, LARRY A. FOX, DESMOND A. SCHATZ, BRANDON M. NATHAN, SANTICA M. MARCONVIA, ROY W. BECK, New Haven, CT, Tampa, FL, Montreal, QC, Canada, Philadelphia, PA, Buffalo, NY, Indianapolis, IN, Denver, CO, Jacksonville, FL, Gainesville, FL, Minneapolis, MN, Seattle, WA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1076-P

Early Detection of Infusion Set Failure during Insulin Pump Therapy in Type 1 Diabetes

MARZIA CESCON, EYAL DASSAU, DANIEL J. DESALVO, TRANG T. LY, DAVID M. MAAHS, LAUREL H. MESSER, BRUCE A. BUCKINGHAM, FRANCIS J. DOYLE III, Santa Barbara, CA, Stanford, CA, Aurora, CO, Denver, CO

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

1096-P

International Differences in the Use of Non-insulin Medications as Adjunctive Therapy in Type 1 Diabetes

KELLEE M. MILLER, JULIA M. HERMANN, DAVID M. MAAHS, MICHAELA RIEDL, LINDA A. DIMEGLIO, ROY W. BECK, REINHARD W. HOLL, Tampa, FL, Ulm, Germany, Aurora, CO, Vienna, Austria, Indianapolis, IN

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1097-P

Short-Term Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) of AZP-531, an Unacylated Ghrelin (UAG) Analog in Healthy and Overweight/Obese Subjects

SORAYA ALLAS, THOMAS DELALE, BETTY NGO, MICHEL JULIEN, PIERRE SAHAKIAN, JAMES RITTER, AART JAN VAN DER LELY, THIERRY ABRIBAT, Écully, France, Overland Park, KS, London, United Kingdom, Rotterdam, Netherlands

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1107-P

Efficacy and Tolerability of 39 Wks of ITCA 650 (Continuous Subcutaneous Exenatide) in Poorly Controlled T2DM with High Baseline A1c (>10%)

ROBERT R. HENRY, JULIO ROSENSTOCK, DOUGLAS S. DENHAM, PRAKASH PRABHAKAR, LISE KJEMS, MICHELLE BARON, San Diego, CA, Dallas, TX, San Antonio, TX, Boston, MA

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1127-P

Once-Weekly Dulaglutide Does Not Increase the Risk for CV Events in Type 2 Diabetes: A Prespecified CV Meta-analysis of Prospectively Adjudicated CV Events

KEITH C. FERDINAND, PHILIP T. SAGER, CHARLES M. ATISSO, FADY T. BUTROS, New Orleans, LA, San Francisco, CA, Indianapolis, IN

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1131-P

Blinded Comparison of Expert Endocrinologists Adjustment of Insulin Pump Settings vs. Novel Initialization Algorithm-based Adjustment following a Data Gathering Period in a Multicenter Closed-Loop RCT

YOGISH C. KUDVA, STEPHEN K. PATEK, SUE BROWN, ANANDA BASU, JORDAN PINSKER, DAVID KERR, JOON BOK LEE, RAVI GONDHALEKAR, DAYU LV, MICHELE SCHIAVON, CHIARA DALLA MAN, BORIS P. KOVATCHEV, CLAUDIO COBELLI, HOWARD C. ZISSER, FRANCIS DOYLE, EYAL DASSAU, Rochester, MN, Charlottesville, VA, Crozet, VA, Santa Barbara, CA, Charlottesville, CA, Padova, Italy

Hall B - Poster Hall

6-Jun

11:30 AM- 1:30 PM

 

 

 

 

 

 

1136-P

Prominent Improved Glycemic Control and Anti-obesity Effects alongside Significant Elongated Pharmacokinetic Profile following Administration of MOD-6031—A Novel Long-Acting Dual GLP-1/Glucagon Agonist

LITAL ISRAELI YAGEV, AHUVA BAR ILAN, VERED LEV, GILI HART, OREN HERSHKOVITZ, Ness Ziona, Israel

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1138-P

Comparative Usability Study of Two Once-Weekly GLP-1RA Pen Injector Products: Tanzeum™ and Bydureon®

ANTHONY D. ANDRE, CATHERINE WANG, BARBARA BERRY, ALICE LOPER, Saratoga, CA, King of Prussia, PA, Menlo Park, CA

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1164-P

Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels

JEFFREY H. BURTON, MATTHEW JOHNSON, JOLENE JOHNSON, DANIEL S. HSIA, FRANK L. GREENWAY, MARK L. HEIMAN, Baton Rouge, LA, New Orleans, LA, Indianapolis, IN

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1165-P

A Novel Dual Pancreatic and Hepatic Acting Glucokinase Activator, HMS5552: Phase I Studies in Healthy Subjects and T2DM Patients

DALONG ZHU, YANHUA DING, DAWEI XIAO, HONGWEI FAN, PEI HU, XUENING LI, XIN GAO, XIAOYING LI, YONGGUO LI, YI ZHANG, LI CHEN, Nanjing, China, Changchun, China, Beijing, China, Shanghai, China

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1169-P

Dose-Ranging Study to Determine the Optimum Dose for Imeglimin, a Novel Treatment for Type 2 Diabetes

PASCALE FOUQUERAY, SEBASTIEN BOLZE, VALDIS PIRAGS, CLIFFORD J. BAILEY, GUNTRAM SCHERNTHANER, SILVIO E. INZUCCHI, JOHN E. GERICH, MICHAEL RODEN, HAROLD E. LEBOVITZ, Lyon, France, Riga, Latvia, Birmingham, United Kingdom, Vienna, Austria, New Haven, CT, Wayne, PA, Düsseldorf, Germany, New York, NY

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1189-P

Effects of the ApoA-I Inducer RVX-208 on Glucose Metabolism in Individuals with Prediabetes

ANDREW L. SIEBEL, MELISSA F. FORMOSA, ALAINA K. NATOLI, MEDINI REDDY-LUTHMOODOO, ANDREW L. CAREY, GERRIT VAN HALL, JIM D. OTVOS, KERRY-ANNE RYE, JAN JOHANSSON, ALLAN GORDON, NORMAN WONG, PHILIP BARTER, STEPHEN J. DUFFY, BRONWYN A. KINGWELL, Melbourne, Australia, Copenhagen, Denmark, Raleigh, NC, Sydney, Australia, Calgary, AB, Canada

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1193-P

Pharmacokinetics and Pharmacodynamics of the Glucagon Receptor Antagonist LGD-6972 in a Multi-dose Clinical Trial

ERIC G. VAJDA, DOUGLAS LOGAN, KENNETH LASSETER, DANIELLE ARMAS, DIANE PLOTKIN, J.D. PIPKIN, YONG-XI LI, RONG ZHOU, DAVID KLEIN, XIAOXIONG WEI, STACY DILZER, LIN ZHI, KEITH B. MARSCHKE, La Jolla, CA, Cincinnati, OH, Miami, FL, Phoenix, AZ, San Diego, CA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1195-P

Pioglitazone Is Equally Effective for Diabetes Prevention in Older Compared with Younger Prediabetic Adults

    SARA E. ESPINOZA, CHENIN WANG, STEPHEN CLEMENT, DAWN SCHWENKE, MARY ANN BANERJEE, GEORGE BRAY, THOMAS A. BUCHANAN, ROBERT HENRY, ABBAS KITABCHI, SUNDER MUDALIAR, ROBERT RATNER, FRANKIE STENTZ, PETER REAVEN, RALPH A. DEFRONZO, DEVJIT TRIPATHY, NICOLAS MUSI, San Antonio, TX, Falls Church, VA, Tempe, AZ, Brooklyn, NY, Baton Rouge, LA, Los Angeles, CA, La Jolla, CA, Memphis, TN, Alexandria, VA, Phoenix, AZ

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1198-P

Reductions in HbA1c and Systolic Blood Pressure in Patients with Type 2 Diabetes Treated with Dapagliflozin

JASON MORAN, ARIE KATZ, HELEN YEH, Fort Washington, PA

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

1201-P

Breadth of DPP-4i Cardiovascular Outcomes Trials Enrollment Criteria to the Whole Type 2 Diabetes Population in the U.S.

ANNE L. PETERS, JOANNA P. MACEWAN, JOHN SHEEHAN, JACQUELINE VANDERPUYE-ORGLE, IFTEKHAR KALSEKAR, ANUP MALANI, Los Angeles, CA, Fort Washington, PA, Chicago, IL

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1202-P

Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF-06291874 (PF), a Glucagon Receptor Antagonist, in Subjects with T2DM

DAVID J. KAZIERAD, ARTHUR BERGMAN, BEESAN TAN, VEENA SOMAYAJI, DOUGLAS S. LEE, TIMOTHY ROLPH, Cambridge, MA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1213-P

Empagliflozin (EMPA) Reduces HbA1c with Lower Insulin Doses in Patients with Type 1 Diabetes (T1DM): A 4-Week Placebo-Controlled Trial (EASE-1)

THOMAS R. PIEBER, SUSANNE FAMULLA, JENS EILBRACHT, JESSICA CESCUTTI, NIMA SOLEYMANLOU, ODD ERIK JOHANSEN, HANS J. WOERLE, ULI C. BROEDL, STEFAN KASPERS, Graz, Austria, Neuss, Germany, Biberach, Germany, Reims, France, Burlington, VT, Asker, Norway, Ingelheim, Germany

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

1223-P

Combined Treatment with Saxagliptin + Dapagliflozin Improves ß-Cell Function and Reduces Insulin Levels by Increased Insulin

    ELLA ELKHOLM, LARS HANSEN, NAYYAR IQBAL, BJÖRN CARLSSON, HUNGTA CHEN, BOAZ HIRSHBERG, Mölndal, Sweden, Princeton, NJ, Gaithersburg, MD

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

1235-P

The SGLT2 Inhibitor Dapagliflozin Decreases Body Weight by Inducing Visceral Fat Tissue Loss in the Early Stage of Treatment

    KEIICHIRO NAKAMAE, IZURU MASUDA, HIDEKI HIGE, BUN CHIN, ARATA IWASAKI, KATSUYO TODA, MASARU IMAI, SEIJI KUROSE, NOBUYUKI AZUMA, HIDESHI KUZUYA, Kyoto, Japan

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

1241-P

Empagliflozin (EMPA) Decreases Glucose Exposure and Variability in Patients with Type 1 Diabetes (T1DM): Continuous Glucose Monitoring (CGM) Data (EASE-1)

    SUSANNE FAMULLA, THOMAS R. PIEBER, JENS EILBRACHT, DIETMAR NEUBACHER, NIMA SOLEYMANLOU, HANS J. WOERLE, ULI C. BROEDL, STEFAN KASPERS, Neuss, Germany, Graz, Austria, Biberach, Germany, Ingelheim, Germany, Burlington, VT

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

1271-P

TTP399, a Liver Selective Glucokinase Activator, Increases Efficacy of Currently Marketed Therapies for Type 2 Diabetes

CARMEN VALCARCE, TUNG M. FONG, High Point, NC, Somerset, NJ

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1296-P

Efficacy and Safety of Alirocumab in Individuals with Diabetes: Analyses from the ODYSSEY LONG TERM Study

HELEN M. COLHOUN, HENRY N. GINSBERG, LAWRENCE A. LEITER, UMESH CHAUDHARI, CHRISTELLE LORENZATO, ROBERT PORDY, JENNIFER G. ROBINSON, Dundee, United Kingdom, New York, NY, Toronto, ON, Canada, Bridgewater, NY, Chilly-Mazarin, France, Tarrytown, NY, Iowa City, IA

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1337-P

Real-World Outcomes of Patients with Type 2 Diabetes Mellitus (T2DM) Treated with Canagliflozin in a U.S. Managed Care Setting

    WING CHOW, ERIN K. BUYSMAN, MARCIA FT. RUPNOW, HENRY J. HENK, Raritan, NJ, Eden Prairie, MN

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

1346-P

Simple CSII Is Highly Cost-Effective

 OLE HENRIKSEN, MADS DALL, JAY WARNER, CHRISTOPHER PARKIN, Copenhagen, Denmark, Hellerup, Denmark, Marlborough, MA, Boulder City, NV

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

1350-P

The Impact of Hypoglycemia on Health Care Use and Costs in T2DM Patients Newly Initiated on Basal Insulin

MEHUL R. DALAL, MAHMOOD KAZEMI, FEN YE, LIN XIE, Bridgewater, NJ, Ann Arbor, MI

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1489-P

Obesity and Cardiovascular Risk: Effects of Dual Therapy Intensification with a DPP-4 Inhibitor Compared with Insulin

ISKANDAR IDRIS, JIL MAMZA, RAJ MEHTA, RICHARD DONNELLY, Derby, United Kingdom, Nottingham, United Kingdom

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1497-P

Cardiovascular Safety of GLP-1 Receptor Agonists (GLP-1-RA) vs. Other Antidiabetic Agents in Routine Care

ELISABETTA PATORNO, BRENDAN EVERETT, ALLISON GOLDFINE, JUN LIU, ROBERT J. GLYNN, SEOYOUNG KIM, Boston, MA

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1501-P

Cardiovascular Risk Factors after Lifestyle Intervention in Prediabetes: Findings from the D-CLIP Trial

  LISA R. STAIMEZ, H RANJANI, MOHAMMED K. ALI, RANJIT MOHAN ANJANA, VISWANATHAN MOHAN, K.M. VENKAT NARAYAN, MARY BETH WEBER, Atlanta, GA, Chennai, India

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1570-P

Clinical Decision Support to Enhance Prediabetes Screening in Primary Care

HUI PENG, SAMEER DESALE, STEPHEN FERNANDEZ, NAWAR SHARA, SAYF YASSIN, DANIEL MERENSTEIN, JOHN JANAS, PETER BASCH, VANITA R. ARODA, Washington, DC, Hyattsville, MD, Concord, NH, Columbia, MD

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1587-P

Mortality in Youth-Onset Diabetes: The SEARCH for Diabetes in Youth Study

   KRISTI REYNOLDS, JASMIN DIVERS, SCOTT ISOM, SHARON SAYDAH, JEAN M. LAWRENCE, DANA M. DABELEA, ELIZABETH J. MAYER-DAVIS, GIUSEPPINA IMPERATORE, RONNY A. BELL, RICHARD F. HAMMAN, Pasadena, CA, Winston-Salem, NC, Atlanta, GA, Aurora, CO, Chapel Hill, NC

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1703-P

Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated with an Increased Risk of Acute Pancreatitis in High-risk Type 2 Diabetic Patients: A Nationwide Cohort Study

   CHIA-HSUIN CHANG, YI-CHENG CHANG, JOU-WEI LIN, SHU-TING CHEN, MEI-SHU LAI, LEE-MING CHUANG, Taipei, Taiwan

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

1722-P

Factors Involved in Predicting Time to Type 1 Diabetes in Antibody Positive TrialNet Subjects

ALEXANDRA R. FOUTS, LAURA PYLE, LIPING YU, DONGMEI MIAO, AARON W. MICHELS, JEFFREY P. KRISCHER, JAY M. SOSENKO, PETER A. GOTTLIEB, ANDREA K. STECK, TYPE 1 DIABETES TRIALNET STUDY GROUP, Aurora, CO, Tampa, FL, Miami, FL

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1724-P

Predictors of Slow Progression to Diabetes in Children with Multiple Islet Autoantibodies

ANDREA K.. STECK, FRAN DONG, KATHLEEN C. WAUGH, LIPING YU, JILL M.. NORRIS, MARIAN REWERS, Aurora, CO, Denver, CO

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1729-P

Hemoglobin A1c and Mortality in Adults with Type 1 Diabetes: Updated Analysis from the Pittsburgh Epidemiology of Diabetes Complications (EDC) Cohort

TREVOR J. ORCHARD, RACHEL G. MILLER, TINA COSTACOU, Pittsburgh, PA

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1731-P

GAD Autoantibody Remission Associated with Risk of Type 1 Diabetes: TEDDY Study

KENDRA VEHIK, KRISTIAN LYNCH, BEENA AKOLKAR, WILLIAM A. HAGOPIAN, MARIAN REWERS, JIN-XIONG SHE, OLLI G. SIMELL, JORMA TOPPARI, ANETTE G. ZIEGLER, AKE LERNMARK, DESMOND SCHATZ, EZIO BONIFACIO, JEFFREY P. KRISCHER, AND THE TEDDY STUDY, Tampa, FL, Bethesda, MD, Seattle, WA, Aurora, CO, Augusta, GA, Turku, Finland, Munich, Germany, Malmö, Sweden, Gainesville, FL, Dresden, Germany

 Hall B - Poster Hall

6-Jun

11:30 AM - 1:30 PM

1744-P

Can Genomic Information Aid in Establishing Aetiology of Young Adult Onset Diabetes?

FOTINI K. KAVVOURA, LOUKAS MOUTSIANAS, AMANDA J. BENNETT, ANUBHA MAHAJAN, NEIL ROBERTSON, N. WILLIAM. RAYNER, CHRISTOPHER J. GROVES, KATHARINE R. OWEN, MARK I. MCCARTHY, Oxford, United Kingdom

 Hall B - Poster Hall

8-Jun

12:00 PM - 2:00 PM

1788-P

A Genetic Risk Score of 96 Variants Linked with Type 2 Diabetes and Cardiometabolic Risk Traits Is Associated with Cardiovascular Mortality in 29-Years Follow-up of the Framingham Heart Study (FHS)

MARCO DAURIZ, BIANCA C.. PORNEALA, JOSÉE DUPUIS, JOANNE M. MURABITO, L. ADRIENNE CUPPLES, JOSE C. FLOREZ, JAMES B. MEIGS, Verona, Italy, Boston, MA

 Hall B - Poster Hall

8-Jun

12:00 PM - 2:00 PM

1841-P

Successful Implementation of Fully Automated Closed Loop Therapy after Islet Autotransplantation

    GREGORY P. FORLENZA, BRANDON NATHAN, ANTOINETTE MORAN, TY B. DUNN, GREGORY J. BEILMAN, TIMOTHY L. PRUETT, MELENA D. BELLIN, Minneapolis, MN

 Hall B - Poster Hall

7-Jun

12:00 PM - 2:00 PM

2340-P

The Effects of SGLT2 Inhibitor on Pancreatic ß-Cell Regeneration and Glucose Homeostasis in Type 1 Diabetes

    SAM TSZ WAI CHENG, STEPHEN YU TING LI, ERIC MAYOUX, PO SING LEUNG, Hong Kong, China, Ingelheim, Germany

 Hall B - Poster Hall

7-Jun

12:00 PM- 2:00 PM

2550-PO

 

 

 

Insulin Degludec/Liraglutide (IDegLira) Improves Patient-Reported Impacts in Subjects with Type 2 Diabetes (T2D) Inadequately Controlled on Insulin Glargine (IG) plus Metformin (Met): DUAL V Study

MERYL BROD, FEDERICO C. PÉREZ MANGHI, PEDRO A. GARCÍA-HERNÁNDEZ, PAUL NORWOOD, HENRIK JARLOV, JENS HARALD KONGSØ, ILDIKO LINGVAY, Mill Valley, CA, Buenos Aires, Argentina, Monterrey, Mexico, Fresno, CA, Søborg, Denmark, Bagsværd, Denmark, Dallas, TX

 

 

 

2616-PO

A Systematic Review of the Comparative Effectiveness and Safety of SGLT2 Inhibitors in Type 2 Diabetes

    EVA TSENG, SHARI BOLEN, JODI B. SEGAL, LISA WILSON, SUSAN HUTFLESS, NISA M. MARUTHUR, Baltimore, MD, Shaker Heights, OH

 

 

 

2656-PO

Using Instagram to Improve Outcomes in Adolescents with Type 1 Diabetes (T1D): A Feasibility Study

JOYCE P. YI-FRAZIER, CONNOR MITROVICH, MICHAEL PASCUAL, KATHERINE COCHRANE, NATALIE BEAUREGARD, KATHERINE VELASCO, NEIL PANLASIGUI, BAILEY CLOPP, ARSHIYA A. BAIG, FAISAL S. MALIK, Seattle, WA, Chicago, IL

 

 

 

2832-PO

Insulin Signaling in Brain Is Increased in Insulin-resistant States—A Link to Alzheimer’s?

 MINI P. SAJAN, ROBERT IVEY, MARGARET FARESE-HIGGS, JOSHUA SAJAN, SHIJE SONG, CSILLA ARI, MICHAEL LEITGES, BARBARA HANSEN, ROBERT FARESE, Tampa, FL, Oslo, Norway

 

 

 

 

-- by Varun Iyengar, Manu Venkat, and Kelly Close